It is anticipated that these agents would contribute to alleviating epilepsy by enhancing the K+ buffering function of astrocytes, thereby lowering both [K+]o and [glutamate]o levels in tripartite synapses, and by reducing the astrocyte expression and secretion of BDNF. This evidence concerns the gene BDNF and epilepsy.